Aehr Points to Silicon Photonics as a 15–20% FY27 Revenue Stream, But Shipment Proof Remains the Gating Factor

What happened

Zacks reports Aehr expects silicon photonics to account for 15–20% of fiscal 2027 revenue, driven by customer ramps and new orders. This adds a second growth vector to the existing hyperscaler Sonoma burn-in program, potentially reducing concentration from the lead AI customer that represented 42.1% of revenue in Q2 FY26. Yet the company's most recent 10-Q shows Q2 FY26 revenue down 44% YoY to $10.3M with a net loss of $(3.2)M, evidencing that bookings have not yet converted into shipments. The DeepValue master report rates AEHR WAIT at $115.3, requiring sequential revenue acceleration and margin improvement tied to actual Sonoma deliveries before underwriting the ramp. The silicon photonics target provides a concrete near-term diversification metric to monitor but does not by itself change the core proof burden around shipment cadence and execution.

Implication

For investors, the 15–20% silicon photonics revenue projection for FY27 is a positive but unproven diversification signal that should be tracked against reported segment or product-line revenue, not just press releases. If silicon photonics customers ramp as stated and the lead hyperscaler begins taking Sonoma deliveries from the upgraded contract manufacturer, Aehr could finally show the sequential revenue inflection missing in recent quarters. However, until the next 10-Q demonstrates YoY growth, improved gross margin, and a reduction in top-customer concentration below 25%, the margin of safety at $115.3 remains absent. The stock already prices steep acceleration, and any delay in converting the $41M April production order into FY27 shipments would likely push valuation toward the bear-case $85 boundary. We maintain a WAIT rating: add only if shipment and mix evidence materializes, and exit or reduce if new dilution or customer pushouts appear.

Thesis delta

The new information quantifies silicon photonics as a 15–20% FY27 revenue contributor, which modestly strengthens the diversification angle but remains unverified. The core thesis—shipment proof and margin recovery from hyperscaler Sonoma orders—is unchanged. The WAIT rating stands, with silicon photonics now a secondary monitoring metric.